Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Price:
2.1
USD
-21.35%
Market Closed
Market Cap:
$151.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
|
US |
|
BayWa AG
XETRA:BYW6
|
DE |
|
E
|
Electricity Generating PCL
SET:EGCO
|
TH |
|
Dayu Water-saving Group Co Ltd
SZSE:300021
|
CN |
|
Fastenal Co
NASDAQ:FAST
|
US |
|
P
|
PAL Group Holdings Co Ltd
TSE:2726
|
JP |
|
Softchoice Corp
F:90Q
|
CA |
|
Fenix Outdoor International AG
STO:FOI B
|
CH |
|
Beam Global
NASDAQ:BEEM
|
US |
|
S
|
Shalag Industries Ltd
TASE:SALG
|
IL |
|
N
|
Nordisk Bergteknik AB (publ)
STO:NORB B
|
SE |
|
P
|
Prism Resources Inc
XTSX:PRS
|
CA |
|
W
|
Wuxi Xuelang Environmental Technology Co Ltd
SZSE:300385
|
CN |
|
CDA SA
F:6LC
|
PL |
|
H
|
Habco Trans Maritima Tbk PT
IDX:HATM
|
ID |
|
Z
|
Zhejiang Yasha Decoration Co Ltd
SZSE:002375
|
CN |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
US |
|
Canoo Inc
NASDAQ:GOEV
|
US |
Multiples-Based Value
The Multiples-Based Value of one
ZNTL
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 2.1 USD,
Zentalis Pharmaceuticals Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ZNTL Multiples-Based Value
LOCKED
Multiples Across Competitors
ZNTL Competitors Multiples
Zentalis Pharmaceuticals Inc Competitors
Zentalis Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
|
151.7m USD | 5.6 | -1 | 0.8 | 0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.1 | 88.4 | 14.7 | 20.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 109.4 | -1 708.3 | 15 870 | -1 791.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.7 | 19.6 | 12.3 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.2 | 27.8 | 20.9 | 21.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.2 | 35.1 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
